Status: Recruiting

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma

Participants needed: 30

Trial details

Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyUpdated: Mar 17, 2026Locations: 1

Eligibility criteria

Male or female, aged ≥18 years. [+10]

Females who are pregnant or lactating. [+11]

Status: Not yet recruiting

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.

Participants needed: 17

Trial details

Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyUpdated: Sep 9, 2025Locations: 1

Eligibility criteria

Male or female, aged ≥18 years. [+9]

Females who are pregnant or lactating. [+12]

Clinical trials

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.